date,title,source
Oct-17-18,Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy,GlobeNewswire
Oct-18-18,Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimers Disease Agitation,GlobeNewswire
Nov-01-18,"Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018",GlobeNewswire
